Abstract

Biotechnology investments have been historically rewarding, but with the recent advances in and excitement about mapping the human genome, interest in this sector has been explosive. As the boundaries between life sciences and information sciences blur and the disciplines cross-fertilize, new business models are emerging for endeavours encompassing gene identification and therapeutic drug targeting. Yet competition is strong and drug development is costly. Picking the winners demands reliance on the fundamental principals of sound investing.